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The ‘cognitive footprint’ of psychiatric and
neurological conditions: cross-sectional
study in the UK Biobank cohort
Cullen B, Smith DJ, Deary IJ , Evans JJ, Pell JP. The ‘cognitive
footprint’ of psychiatric and neurological conditions: cross-sectional
study in the UK Biobank cohort.
Objective: We aimed to quantify the prevalence of cognitive
impairment in adults with a history of mood disorder, schizophrenia,
multiple sclerosis or Parkinson’s disease, within a large general
population cohort.
Method: Cross-sectional study using UK Biobank data
(n = 502 642). Psychiatric and neurological exposure status was
ascertained via self-reported diagnoses, hospital records and
questionnaires. Impairment on reasoning, reaction time and memory
tests was defined with reference to a single unexposed comparison
group. Results were standardised for age and gender. Sensitivity
analyses examined the influence of comorbidity, education,
information sources and missing data.
Results: Relative to the unexposed group, cognitive impairment was
least common in major depression (standardised prevalence ratios
across tests = 1.00 [95% CI 0.98, 1.02] to 1.49 [95% CI 1.24, 1.79]) and
most common in schizophrenia (1.89 [95% CI 1.47, 2.42] to 3.92 [95%
CI 2.34, 6.57]). Prevalence in mania/bipolar was similar to that in
multiple sclerosis and Parkinson’s disease. Estimated population
attributable prevalence of cognitive impairment was higher for major
depression (256 per 100 000 [95% CI 130, 381]) than for all other
disorders.
Conclusion: Although the relative prevalence of cognitive impairment
was lowest in major depression, the population attributable prevalence
was highest overall for this group.
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Significant outcomes
• Cognitive impairment in bipolar disorder has previously received less research and clinical
attention than impairment in schizophrenia and neurological disorders, but direct comparisons
in the present study indicated that impairment prevalence in mania/bipolar disorder was similar
to that in multiple sclerosis and Parkinson’s disease, both of which are much less common in
the population.
• As in previous clinical studies, cognitive impairment was found to be most common in participants
with schizophrenia and least common in those with major depression.
• The high population prevalence of major depression means that the overall burden of cognitive
impairment attributable to this disorder is likely to be considerable.
593
Acta Psychiatr Scand 2017: 135: 593–605 © 2017 The Authors. Acta Psychiatrica Scandinavica Published by John Wiley & Sons Ltd.
All rights reserved
DOI: 10.1111/acps.12733
ACTA PSYCHIATRICA SCANDINAVICA
Limitations
• Information regarding exposure status relied substantially on self-reported diagnoses or responses to
questionnaire items.
• The cognitive tests were brief and did not assess long-term episodic memory or complex executive
skills, which are often impaired in people with psychiatric or neurological conditions.
• The UK Biobank cohort is not representative of the UK population in some respects, and the expo-
sure groups that we identified within it are likely to differ from psychiatric and neurological samples
in other studies and in clinical practice, with regard to sociodemographic characteristics, illness sever-
ity and motivational factors.
Introduction
Psychiatric and neurological conditions are associ-
ated with cognitive impairment, which contributes
to chronic disability, reduced wellbeing and quality
of life, and restricted social and economic partici-
pation. This ‘cognitive footprint’ (1) will be evident
over many years, with impact being particularly
marked in common conditions and in those with
younger age at onset. Cognitive impairment has
long been a focus of research in chronic neurologi-
cal conditions such as multiple sclerosis (MS) and
Parkinson’s disease (PD), as well as severe psychi-
atric disorders such as schizophrenia, with atten-
tion turning more recently to the cognitive impact
of common mental health conditions. The cogni-
tive burden of these chronic conditions is of great
public health importance: interventions to prevent
or manage associated cognitive impairment have
the potential ‘to foster cognitive health and to pre-
serve cognitive capital’ (1) at both individual and
societal levels. Mood disorders, schizophrenia, MS
and PD are particularly important to consider in
this context: unlike the dementias, average age of
onset of these disorders is under 65 years, and their
chronic illness course means that individuals may
live with cognitive impairment for many years.
In people with mood disorders, for example, cog-
nitive impairment persists between illness episodes
and contributes substantially to ongoing disability
(2, 3). This impacts negatively on functional inde-
pendence, educational and occupational attain-
ment, and quality of life (4–7), and cognitive
improvement is therefore an increasing focus of
treatment development efforts (8–10). Estimates of
cognitive impairment prevalence in euthymic adults
with mood disorder vary considerably, ranging
from 5% to 58% in adults with bipolar disorder
(BD) (11), and from one-third to one-half in those
with major depressive disorder (12). Cognitive
impairment is evident in the majority of people with
schizophrenia – possibly as many as 80% – and has
been proposed as a core diagnostic criterion (13,
14). Community-based studies have reported cogni-
tive impairment prevalence of 44%–48% in people
with MS (15) and 50%–55% in those with PD (16).
Comparative burden of cognitive impairment
across disorders must be considered with reference
to the relative prevalence of the disorders them-
selves. In the United Kingdom, lifetime prevalence
per 100 000 population is estimated at up to
10 000 for major depression (17) and approxi-
mately 1 000 for BD (18), compared with 400–
1 000 for schizophrenia (19) and 200 for both MS
and PD (20). Despite the greater research focus on
cognitive function in schizophrenia and neurologi-
cal disorders, it is clear that the higher prevalence
of mood disorders in the population means that
the absolute number with associated cognitive
impairment is likely to be substantial and of signifi-
cant public health importance.
Previous studies of cognitive function in various
psychiatric and neurological conditions are diffi-
cult to compare directly, because of variations in
source populations, methods of recruitment,
assessment tools, impairment definitions, composi-
tion of normative comparison groups and adjust-
ment for potential confounders. The UK Biobank
general population cohort presents an opportunity
to overcome these limitations. UK Biobank
recruited more than half a million adults in middle
and early old-age, with baseline assessment of
medical history, cognitive function, sociodemo-
graphic characteristics and lifestyle factors, as well
as linkage to hospital records (21). It is therefore
possible to compare cognitive impairment preva-
lence directly across conditions, using the same
measures and impairment thresholds, taking
account of confounders that have been measured
in a standardised way.
Aims of the study
In this cross-sectional study, we aimed to quantify
the prevalence of cognitive impairment in adults
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with a history of mood disorder, schizophrenia,
MS or PD, in the UK Biobank cohort. Standard-
ised direct comparisons will contribute to a clearer
picture of the relative frequency of cognitive
impairment in these conditions, as well as the mag-
nitude of attributable prevalence at the population
level. This enables both a disorder-specific and a
general population-level appreciation of the ‘cogni-
tive footprint’ of key psychiatric and neurological
conditions affecting working-age adults.
Material and methods
Participants
Adults aged 40–69 years who were registered with
the National Health Service (NHS) and living
within 25 miles of a study assessment centre were
invited by post to participate in UK Biobank, with
a response rate of approximately 6% (22). Data
from the full cohort at baseline (n = 502 642) were
used in the present study. All participants gave
written informed consent. This study was con-
ducted under generic approval from the NHS
National Research Ethics Service (Ref. 11/NW/
0382), and the data were obtained from UK Bio-
bank under application 11332.
Materials and procedure
Baseline assessments took place at 22 centres
across England, Scotland and Wales between 2006
and 2010. Participants attended a single visit last-
ing approximately 2–3 h, encompassing consent
processes, computerised touch screen question-
naire, nurse interview and physical measurements.
Assessments were administered in a standardised
order. Key sociodemographic information for the
present study included age, gender and educational
attainment (dichotomised according to whether or
not participants held a university/college degree).
Full details of demographic, lifestyle and psycho-
logical measures are given in Appendix S4 and
Appendix S1. Information regarding minimisation
of bias in the study procedures is provided in
Appendix S4.
History of psychiatric and neurological condi-
tions. Psychiatric and neurological conditions
were studied as risk factors for the outcome of cog-
nitive impairment. The conditions of interest in the
present study were mania/BD, major depression
(single or recurrent episodes), schizophrenia, MS
and PD. Three data sources were used to ascertain
whether participants were ‘exposed’ to any of the
conditions of interest: self-reported diagnoses;
linked NHS hospital records; and a touch screen
mood disorders questionnaire.
Self-reported diagnoses. All participants were
asked whether they had ever been told by a doctor
that they had a serious illness or disability.
Responses were recorded during the nurse inter-
view and were subsequently assigned unique codes.
Conditions of interest were manually coded for the
present study, as listed in Appendix S2. Partici-
pants reporting both mania/BD (‘mania/bipolar/
manic depression’) and major depression (‘depres-
sion’ or ‘postnatal depression’) were classified as
mania/BD.
Linked hospital records. Medical history was also
available from hospital records, retrieved by UK
Biobank from NHS data providers across the UK
and linked centrally to UK Biobank data using
participant identifiers. Data were analysed from
in-patient and day-case admissions to NHS hospi-
tals between the mid-1990s (varied by country) and
the UK Biobank baseline assessment date. ICD-10
codes from primary or secondary positions in the
hospital records were used to identify participants
with conditions of interest (Appendix S3). Hospital
records from England and Wales included both
general and psychiatric hospitals, but records from
Scotland covered general hospitals only. Partici-
pants in Scotland (7.1% of the whole cohort) were
therefore coded as ‘missing’ when ascertaining the
mania/BD, major depression and schizophrenia
groups using ICD data, but they contributed ICD
data when ascertaining the MS and PD groups.
Participants with ICD-10 codes for both mania/
BD (F30x or F31x) and major depression (F32x or
F33x) were classified as mania/BD.
Mood disorders questionnaire. A third ascertain-
ment method was available to identify history of
mania/BD or major depression, based on the UK
Biobank baseline touch screen questionnaire (final
2 years of baseline recruitment only). As described
by our group previously (23), responses to ques-
tions regarding lifetime experience of depressive
and manic symptoms and medical help-seeking for
mental health were used to identify participants
with a probable lifetime history of mania/BD or
major depression. Participants meeting criteria for
both disorders were classified as mania/BD. We
have previously described cognitive performance
in these groups (24).
Exposed and unexposed group definitions. Exposure
status for each condition of interest (mania/BD,
major depression, schizophrenia, MS and PD) was
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classified in two ways, using ‘broad’ and ‘narrow’
definitions. Participants who met criteria for the
condition according to at least one ascertainment
source were classified in the broadly defined expo-
sure group, and participants who met criteria
according to at least two ascertainment sources were
classified in the narrowly defined exposure group.
A single comparison group was constructed as a
common reference for all of the exposure groups.
Participants in this group were considered to be
unexposed with regard to the conditions of interest
in this study, as well as any other psychiatric con-
dition or any condition affecting brain function.
This group met all of the following criteria: pro-
vided data on the mood disorders questionnaire
and were not classified in the mania/BD or major
depression groups (mild subthreshold symptoms
were permitted); no hospital ICD-10 code of any
psychiatric or brain condition (as listed in
Appendix S3); no self-reported diagnosis of any
psychiatric or brain condition (as listed in
Appendix S2). Participants who did not meet crite-
ria for any of the exposed or unexposed groups
were not further analysed.
Cognitive function. Cognitive tests were adminis-
tered visually via a touch screen. The tests are
described briefly below, and full details are pro-
vided in Appendix S4.
Reasoning. Verbal and numerical problems were
presented on-screen, and participants were asked
to choose the correct response from multiple
options. Although referred to as the ‘fluid intelli-
gence’ test in the UK Biobank protocol, perfor-
mance on some of the items was thought to rely on
crystallised knowledge, and so we refer to it simply
as a reasoning test. The score was an unweighted
total of correct responses, from 0 to 13.
Reaction time. Psychomotor speed was measured
by pressing a button as quickly as possible each
time a matching pair of symbols was presented on-
screen. The score was the mean time in millisec-
onds across trials.
Numeric memory. This test was intended to assess
working memory. A string of numbers was pre-
sented on-screen, and after a brief delay, partici-
pants were asked to enter it from memory, in
reverse order, via a numeric keypad. The score was
the maximum string length recalled correctly.
Pairs matching. In this test of visual memory, sym-
bol cards were presented on-screen in a random
array. Participants were asked to memorise the
position of matching pairs. The cards were then
turned face down, and participants were asked to
touch as many matching pairs as possible in the
fewest tries. The score was the number of errors
made whilst attempting to select the pairs.
Prospective memory. An instruction was given on-
screen asking participants to select a certain shape
from an array that would be presented later in the
assessment process. When the array later
appeared, participants were given up to two
chances to select the correct shape. Performance
was scored dichotomously as being correct on the
first attempt or not.
Participants in the exposed groups were classi-
fied as impaired if their score was equal to or worse
than the lowest-performing 5% (or nearest feasible
proportion) of the unexposed group (see
Appendix S4). Since prospective memory was a
categorical measure, impairment in all groups was
defined as being incorrect on the first attempt.
Data analysis
Prevalence of impairment on the five cognitive
tests was calculated in each group, reported as a
percentage with 95% confidence intervals (CI)
based on the standard error calculated as follows:
√((prevalence*(100-prevalence))/n). The ratio of
prevalence in each exposed group vs. the unex-
posed reference group was calculated, together
with 95% CI, using the epitab functions in Stata
v13. Crude results are reported, along with directly
standardised results, which were computed using
weights derived from the unexposed comparison
group. In direct standardisation, sample sizes
within each stratum of an external reference group
(here, the unexposed comparison group) are used
as weights to adjust the stratum-specific prevalence
ratios in the exposed group: the prevalence ratio in
each stratum of the exposed group is multiplied by
the sample size of that stratum in the reference
group, and the resulting products are then summed
and divided by the total sample size of the refer-
ence group, to produce a standardised prevalence
ratio for the whole exposed group. The purpose of
standardisation was to control for demographic
differences between the exposed and unexposed
groups that might confound the crude results;
stratification was by age group (<60 vs. ≥60 years)
and gender. Statistical interactions between expo-
sure status and each of the confounders were tested
using robust Poisson regression models (25)
including a product term. Other descriptive analy-
ses are detailed in Appendix S4.
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The population attributable prevalence of cogni-
tive impairment (number of cases of cognitive
impairment per 100 000 total population that are
attributable to the exposure) was derived from
2 9 2 tables constructed for each exposure sepa-
rately. Prevalence of each exposure within these
tables was based on lifetime estimates cited in the
Introduction. Population attributable prevalence
was calculated as total cases of cognitive
impairment per 100 000 population * population
attributable fraction (PAF), where PAF was
(prevalencetotal-prevalenceunexposed)/prevalencetotal.
Sensitivity analyses were conducted to examine
the effects of several potential sources of bias and
confounding, including comorbidity, education,
information sources and missing data. Details are
provided in Appendix S4. Reporting follows
STROBE guidance (26).
Results
Characteristics of the exposed and unexposed groups
Table 1 shows the characteristics of each group on
key demographic factors and the five cognitive
measures. Additional group characteristics are
provided in Table S1. The total number in the
cohort who did not meet criteria for any of the
exposed groups or the unexposed comparison
group was 336 662; a large number were excluded
from the unexposed group because they were not
administered the mood disorders questionnaire.
The relative sizes of the broadly and narrowly
defined versions of each exposure group were clo-
ser for MS and PD than for the other exposures,
possibly reflecting the greater likelihood of a hospi-
tal admission during the available time period for
participants with these diagnoses. The proportion
of missing data varied across measures, but tended
to be higher in the exposed groups (particularly
those with schizophrenia), compared with the
unexposed comparison group. Cronbach’s alpha is
reported in Table 1 for the reasoning and reaction
time tests in each group; it was not possible to cal-
culate this for the other three cognitive tests, as
they did not include multiple items. Alpha was
higher for reaction time than for reasoning, but
coefficients did not differ notably across groups.
Other psychometric characteristics of the cognitive
tests have been reported by us previously (27).
Prevalence of cognitive impairment across groups
On the reaction time, numeric memory and pairs
matching tests, the cognitive impairment threshold
corresponded to the worst-performing 5% of the
unexposed group. Owing to the restricted raw
score range on the reasoning test, the same raw
score spanned the 5th to 11th percentile range and
so the 4th percentile score was instead used to
divide the sample; the impairment threshold there-
fore corresponded to the worst-performing 4% of
the unexposed group. Prospective memory was a
pass/fail test; the proportion of the unexposed
group with an incorrect score was 22.82%. Table 2
shows prevalence of impairment in each exposed
group, along with prevalence ratios relative to the
unexposed group. Standardised estimates are not
reported for some groups, because of insufficient
data in some strata.
The crude estimates indicated that impairment
prevalence was higher in mania/BD than in the
comparison group, with prevalence ratios in the
broadly defined group ranging from 1.27 (95% CI
1.18, 1.36) to 1.97 (95% CI 1.52, 2.56). Prevalence
in major depression was closer to the comparison
group level, with crude ratios in the broadly
defined group ranging from 0.98 (95% CI 0.96,
1.00) to 1.09 (95% CI 1.04, 1.14). Crude impair-
ment prevalence was higher in MS and PD groups
than in the comparison group on reaction time
(2.87 [95% CI 2.56, 3.22] and 1.34 [95% CI 1.05,
1.72] respectively in the broadly defined groups),
pairs matching (1.42 [95% CI 1.19, 1.69] and 1.89
[95% CI 1.52, 2.35]) and prospective memory (1.17
[95% CI 1.02, 1.33] and 1.27 [95% CI 1.07, 1.52]).
Crude impairment prevalence was highest in
schizophrenia on all tests (prevalence ratios in the
broadly defined group ranged from 1.95 [95% CI
1.73, 2.21] to 3.95 [95% CI 2.43, 6.43]) except reac-
tion time, for which prevalence was highest in MS.
Following direct standardisation with reference
to the unexposed group weights for age group and
gender, estimates increased in the mania/BD and
major depression groups on all measures. Some
estimates increased and some decreased in the
schizophrenia groups, although the general pattern
was similar to the crude results. In MS groups, all
estimates but one increased, and in PD, reasoning
and numeric memory estimates increased but other
estimates decreased. Figure 1 shows the standard-
ised prevalence, and Fig. 2 shows the standardised
prevalence ratios on all measures in the broadly
defined exposure groups.
Evidence of effect measure modification by age
group or gender is highlighted in Table 2, and
stratified results are provided in the footnote.
Within mania/BD, MS and PD groups, interaction
tests indicated that impairment prevalence was sig-
nificantly lower in the older age group on some
measures. Significant interactions with gender were
found in major depression and MS on some
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measures, showing lower impairment prevalence in
women.
When the highest standardised impairment
prevalence estimates from Table 2 were applied to
population prevalence estimates for each illness
exposure (cited in the Introduction), the popula-
tion attributable lifetime prevalence of cognitive
impairment per 100 000 population was approxi-
mately 256 (95% CI 130, 381) for major depres-
sion, 151 (95% CI 52, 251) for schizophrenia, 45
(95% CI 23, 68) for mania/BD, 27 (95% CI 22, 32)
for MS and 26 (95% CI 1, 52) for PD.
Sensitivity analyses
Details of all sensitivity analysis results are pro-
vided in Appendix S5. The key findings were that
crude estimates in the major depression group
attenuated when results were re-calculated in par-
ticipants with no known comorbidities; standard-
ised results remained similar when education was
taken into account along with age group and gen-
der (Table S2); estimates were higher in alternative
mania/BD and major depression groups formed
without reference to the mood disorders question-
naire (Table S3); the characteristics of the MS and
PD groups identified via hospital records were very
similar regardless of whether Scotland data were
included; and participants with missing cognitive
data were older, less likely to have a degree, and
more likely to have comorbidities.
Discussion
In this community-based population in middle to
early old-age, standardised prevalence of cognitive
impairment was higher in people with a history of
psychiatric or neurological conditions than in
those with no such history. Across the exposure
groups studied, standardised prevalence was high-
est on most measures in participants with
schizophrenia and lowest in those with major
depression. Mania/BD was the second most
impaired exposure group on three of five measures
(reasoning, numeric memory and prospective
memory), and sensitivity analyses showed that
impairment in this group was higher still when
exposure information sources were strictly equiva-
lent with the other groups. Reaction time impair-
ment was most prevalent in the MS group, which
is in line with previous research showing particular
problems with processing speed in MS and other
Fig. 1. Standardised prevalence estimates for cognitive impair-
ment. Estimates are prevalence (%), directly standardised by
age and gender with reference to the unexposed comparison
group. Point estimates and 95% confidence intervals are
shown. Exposure groups are broadly defined (classified as
exposed by at least one ascertainment method). Panels show
(a) reasoning; (b) reaction time; (c) numeric memory; (d) pairs
matching; (e) prospective memory.
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white matter disorders (28–30). Although the
increased prevalence (compared with the unex-
posed group) of cognitive impairment in major
depression was relatively small, lifetime prevalence
of major depression is approximately ten times
that of BD and schizophrenia and fifty times that
of MS and PD, which meant that the population
attributable prevalence of cognitive impairment
was highest overall for this group. Sensitivity anal-
yses suggested that comorbidities may be con-
tributing to the increased likelihood of cognitive
impairment in major depression.
This is the first study to directly compare preva-
lence of cognitive impairment across these condi-
tions, using consistent assessment methods and a
single unexposed comparison group. Multiple
sources of information were used to classify expo-
sure status, and impairment status was defined
with reference to a very large normative group.
Direct standardisation permitted like-for-like com-
parisons across exposure groups, and sensitivity
analyses were conducted to examine possible
sources of bias and confounding. The overall pat-
tern of findings was consistent regardless of expo-
sure group definitions (wide or narrow) and
adjustment for key demographic characteristics.
The prevalence of cognitive impairment in all
groups was lower than expected. This may indicate
that people living with psychiatric and neurologi-
cal conditions in the general population are less
impaired than the patient population represented
in clinical studies. Alternatively, the low prevalence
of impairment may reflect selection bias in UK
Biobank, such that invitees may have been more
motivated to join a medical research study if they
had prior experience of health problems, and may
have been more willing or able to take part if they
had better cognitive function and/or less severe dis-
order. This would represent collider bias (31),
whereby exposed status and (lower) probability of
impaired outcome together influenced study partic-
ipation. This would bias any true association of
exposure with impaired outcome towards the null.
Similarly, the greater proportion of missing cogni-
tive data in the exposed groups, and the finding
that missingness was itself associated with older
age, lower educational attainment and
Fig. 2. Standardised prevalence ratios for cognitive impair-
ment. Estimates are prevalence ratios compared to the unex-
posed group, directly standardised by age and gender. Point
estimates and 95% confidence intervals are shown. Exposure
groups are broadly defined (classified as exposed by at least
one ascertainment method). Panels show (a) reasoning; (b)
reaction time; (c) numeric memory; (d) pairs matching; (e)
prospective memory.
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comorbidities, suggests that selection into the anal-
ysed sample was biased towards more cognitively
able participants. It should also be noted that the
brevity and limited domain coverage of the cogni-
tive tests may have led to ceiling effects and/or lack
of sensitivity to impairment in other aspects of
cognitive function, such as long-term episodic
memory and complex executive skills, which
are common in psychiatric and neurological
conditions.
The prevalence of impairment was higher when
mood disorder exposure groups were based on
self-reported doctor diagnosis and/or hospital
records, without reference to questionnaire data
on lifetime mood disorder experiences (Table S2);
the results in Table 2 can therefore be taken as a
lower bound of true prevalence. It may be that the
questionnaire data misclassified participants as
exposed (differentially so for less cognitively
impaired participants), or, alternatively, there
might be a large number of people living with
undiagnosed mood disorders in the general popu-
lation, whose true prevalence of cognitive impair-
ment is lower than previous studies have
suggested.
With regard to demographic factors, our finding
that cognitive impairment was less common in
women compared with men in the MS group on
some measures may reflect generally less severe dis-
ease course in women (32); a similar finding for
women in the major depression group was unex-
pected in the light of a recent review, however (33).
Impairment was also less common in older com-
pared with younger participants within mania/BD,
MS and PD groups. Given the consistent associa-
tion between older age and greater cognitive
impairment in the general population, this finding
is likely to indicate survivor bias, whereby only the
most able or healthy older individuals in these
exposed groups joined UK Biobank or provided
complete data for analysis.
A number of study limitations need to be con-
sidered. Unlike previous studies in these condi-
tions, clinician-confirmed diagnoses were not
available, and linked health records covered in-
patient and day-case admissions only. Psychiatric
hospital data were also missing for Scotland par-
ticipants, although these comprised only 7% of
the whole cohort. Information regarding exposure
status relied substantially on self-reported
diagnoses or responses to questionnaire items.
Nevertheless, descriptive data regarding sociode-
mographic factors, psychological measures and
medication use supported the distinctions between
the groups. The cross-sectional nature of the
study and the limitations of available clinical
information also meant that the onset times and
durations of exposures and outcomes were not
known; exposure-outcome associations may not
be causal, and it is possible that cognitive impair-
ment may precede clinical onset of some disorders
(e.g. schizophrenia). UK Biobank had an invita-
tion response rate of only 6% (22), and the cohort
is not representative of the UK population in
some respects (e.g. health-related behaviours such
as smoking). The exposure groups that we identi-
fied within it are likely to differ from psychiatric
and neurological samples in other studies and in
clinical practice, with regard to sociodemographic
characteristics, illness severity and motivational
factors. It is not known whether the degree of
non-representativeness differed across exposure
groups, however; if it did not, then between-group
comparisons remain valid. Within the mood dis-
order groups, it was not possible to distinguish
reliably between subtypes of bipolar presentations
and single vs. recurrent depression, thus limiting
the comparability of the findings to previous clini-
cal studies. Current depressive symptoms were
reported, but status with regard to clinical euthy-
mia was not known.
We have previously noted some limitations of
the brief cognitive tests (24, 27), and we note here
also that the impairment threshold differed slightly
across the five tests, because of variation in the ref-
erence score distributions. It is possible that the
relatively low impairment prevalence on these cog-
nitive tests compared with previous clinical studies
reflects insensitivity of the brief measures or differ-
ential reliability across exposure groups, but varia-
tion in performance across groups was detectable
whilst internal consistency was similar. Despite the
very large size of the cohort, sample sizes were
modest on some cognitive measures and data were
sparse across strata in the narrowly defined expo-
sure groups, which limited the standardised analy-
ses. No information was available regarding the
impact of cognitive impairment on instrumental
functioning: it is possible that the impact of
impairment on disability and participation is not
well captured by the 5th percentile impairment
threshold used here, given that the range of sever-
ity below this threshold may differ across disor-
ders, and some people will experience instrumental
dysfunction even when measured cognitive perfor-
mance remains above the 5th percentile threshold.
The present study aimed to quantify prevalence
of cognitive impairment in order to permit direct
comparisons of burden across disorders of interest.
Although we took into account potential con-
founding influences of age, gender and education,
more complex analyses are required to investigate
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the multitude of other social, clinical, lifestyle and
genetic factors that are likely to contribute to cog-
nitive risk and resilience in psychiatric and neuro-
logical disorders. It will be possible to explore
these in a multivariate explanatory framework
using a range of data from baseline and follow-up
assessments in UK Biobank, as well as ongoing
extensions to data linkage (34).
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